In AD patients, tau tracers bind specifically in the temporal lobes, including the hippocampus, whereas amyloid-beta tracers bind more diffusely in frontal and parietal cortices (James et al., 2015, Brier et al., 2016, Ossenkoppele et al., 2016). This evidence concerns the gene MAPT and Alzheimer disease.